Stay up to date on PsychoGenics and the world of preclinical drug discovery.
PsychoGenics Announces Exclusive Global License for an IND-ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders
December 1, 2023
AI-discovered drug shows ‘enormous potential’ to treat schizophrenia: ‘Real need for better treatment’
May 10, 2023
PsychoGenics highlights a long-term collaboration with the TSC Alliance on Rare Disease Day
February 28, 2023